# CheckMate 744 (NCT02927769)

> A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02927769
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Hodgkin Disease
- Interventions: Nivolumab; brentuximab vedotin; bendamustine
- Enrollment: 72
- Primary outcome: Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1
- Primary outcome: Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1
- Primary outcome: Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 4
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-744-nct02927769

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02927769", "email": "<work email>"}; the inbox owner confirms by the emailed link.